Caring Ambassadors Program

Hepatitis C Newsletter

www.HepCChallenge.org

 

May 2012

 

 

Clinical Trials, Cohort Studies, Pilot Studies

 

The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance. Yu JW, Sun LJ, Zhao YH, Kang P, Yan BZ. Int J Infect Dis. 2012 Apr 7. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22486858.1

 

Bipolar patients can safely and successfully receive interferon-based hepatitis C antiviral treatment. Kelly EM, Corace K, Emery J, Cooper CL. Eur J Gastroenterol Hepatol. 2012 Apr 8. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22495398.1

 

A retrospective case-control study of hepatitis C virus infection and oral lichen planus in Japan: association study with mutations in the core and NS5A region of hepatitis C virus.

Nagao Y, Sata M. BMC Gastroenterol. 2012 Apr 10;12(1):31. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22490000.1

 

Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. Petta S, Ferraro D, Cammà C, et al. Antivir Ther. 2012 Apr 13. doi: 10.3851/IMP2100. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22505587.1

 

Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection. Clark BT, Garcia-Tsao G, Fraenkel L. Patient Prefer Adherence. 2012;6:285-95. Epub 2012 Apr 4.

http://www.ncbi.nlm.nih.gov/pubmed/22536063.1

 

Vaniprevir with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C - a randomized phase 2 study. Manns MP, Gane E, Rodriguez-Torres M, et al. Hepatology. 2012 Apr 2. doi: 10.1002/hep.25743. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22473713.1

 

 

 

 

 

 

Basic and Applied Science, Pre-Clinical Studies

 

Plasma ribavirin trough concentrations during treatment of chronic hepatitis C in genotype-1 patients. Muñoz-de-Rueda P, Ruiz-Extremera A, Candel JM, et al. J Clin Gastroenterol. 2012 Apr;46(4):328-33.

http://www.ncbi.nlm.nih.gov/pubmed/22105181.1

 

The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C. Brennan BJ, Morcos PN, Wang K, et al. Aliment Pharmacol Ther. 2012 May;35(10):1209-20. doi: 10.1111/j.1365-2036.2012. 05079.x. Epub 2012 Apr 3.

http://www.ncbi.nlm.nih.gov/pubmed/22469033.1

 

Race- and gender-related variation in NKp46 expression associated with differential anti-HCV immunity. Golden-Mason L, Stone AE, Bambha KM, Cheng L, Rosen HR. Hepatology. 2012 Apr 13. doi: 10.1002/hep.25771. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22505144.1

 

RANTES, TNF-α, Oxidative Stress, and Hematological Abnormalities in Hepatitis C Virus Infection. Tawadrous GA, Aziz AA, Amin DG, Eldemery A, Mostafa MA. J Investig Med. 2012 Apr 24. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22534629.1

 

Human pluripotent stem cell derived hepatocytes support complete replication of hepatitis C virus. Roelandt P, Obeid S, Paeshuyse J, et al. J Hepatol. 2012 Apr 17. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22521345.1

 

Persistance of HCV in Quiescent Hepatic Cells during an Interferon-Induced Antiviral Response.  Bauhofer O, Ruggieri A, Schmid B, Schirmacher P, Bartenschlager R. Gastro-enterology. 2012 Apr 18. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22522091

 

The two crucial early steps in RNA synthesis by Hepatitis C virus polymerase involve a dual role of residue 405. Scrima N, Caillet-Saguy C, Ventura M, et al. Virol. 2012 Apr 24. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22532694.1

 

NKp46(High) expression defines a NK cell subset that is potentially involved in control of HCV replication and modulation of liver fibrosis. Krämer B, Körner C, Kebschull M, et al. Hepatology. 2012 Apr 24. doi: 10.1002/hep.25804. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22532190

 

Hepatic Methionine-enkephalin may interfere with response to antiviral therapy in chronic hepatitis C. Floreani A, Antoniazzi S, Mescoli C, Bergasa NV. Eur J Gastroenterol Hepatol. 2012 Apr;24(4):427-30.

http://www.ncbi.nlm.nih.gov/pubmed/22293330.1

A role for TBC1D20 and Rab1 in Hepatitis C virus replication via interaction with LD bound NS5A. Nevo-Yassaf I, Yaffe Y, Asher M, et al. J Virol. 2012 Apr 4. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22491470.1

 

HIV/HCV Coinfection

 

End-stage liver disease: Prevalence, risk factors and clinical characteristics in a cohort of HIV-HCV coinfected Han Chinese. Deng L, Gui X, Xiong Y, et al. Clin Res Hepatol Gastroenterol. 2012 Apr 3. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22481087.1

 

Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals. Martinez V, Ta TD, Mokhtari Z, et al. BMC Res Notes. 2012 Apr 10;5(1):180. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22490728.1

 

Effect of Liver Fibrosis on Long-Term Mortality in HIV/Hepatitis C Virus-Coinfected Individuals Who Are Evaluated to Receive Interferon Therapies in the Highly Active Antiretroviral Therapy Era. Sanmartin R, de Felipe E, Tor J, Sanvicens A, et al. AIDS Res Hum Retroviruses. 2012 Apr 20. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22443303.1

 

HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians.

Ingiliz P, Rockstroh JK. Liver Int. 2012 Apr 17. doi: 10.1111/j.1478-3231.2012.02796.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22510096.1

 

Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients. Macías J, Berenguer J, Japón MA, et al. Hepatology. 2012 Apr 16. doi: 10.1002/hep.25791. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22508322.1

 

Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. Nelson M, Amaya G, Clumeck N, et al. J Antimicrob Chemother. 2012 Apr 24. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22532465.1

 

Dynamic analysis of Th1/Th2 cytokine concentration during antiretroviral therapy of HIV-1/HCV co-infected Patients. Kang W, Li Y, Zhuang Y, Zhao K, Huang D, Sun Y. BMC Infect Dis. 2012 Apr 25;12(1):102. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22533731.1

 

Risk of Elevated Total Cholesterol/High-Density Lipoprotein Cholesterol Ratio After Antiretroviral Therapy in HIV/Hepatitis C Virus Patients. Kakinami L, Adams MJ, Block RC, Cohn SE, Maliakkal B, Fisher SG. AIDS Res Hum Retroviruses. 2012 Apr 10. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22380598.1

 

Complementary and Alternative Medicine

 

25-hydroxyvitamin D(3) suppresses hepatitis C virus production. Matsumura T, Kato T, Sugiyama N, et al. Hepatology. 2012 Apr 6. doi: 10.1002/hep.25763. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22487892.1

 

Spirulina platensis versus silymarin in the treatment of chronic hepatitis C virus infection. A pilot randomized, comparative clinical trial. Yakoot M, Salem A. BMC Gastroenterol. 2012 Apr 12;12(1):32. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22497849.1

 

Epidemiology, Diagnostics, and Miscellaneous Works

 

Tangible Resources for Preparing Patients for Antiviral Therapy for Chronic Hepatitis C.

Bonner JE, Barritt AS 4th, Fried MW, Evon DM. Dig Dis Sci. 2012 Apr 10. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22488633.1

 

Risk factors for liver disease and associated knowledge and practices among Mexican adults in the US and Mexico. Flores YN, Lang CM, Salmerón J, Bastani R. J Community Health. 2012 Apr;37(2):403-11.

http://www.ncbi.nlm.nih.gov/pubmed/21877109.1

 

Update on the Management and Treatment of Hepatitis C Virus Infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Yee HS, Chang MF, Pocha C, Lim J, Ross D, Morgan TR, Monto A. Am J Gastroenterol. 2012 Apr 24. doi: 10.1038/ajg.2012.48. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22525303.1

 

National patterns and predictors of liver biopsy use for managing hepatitis C. Groessl EJ, Liu L, Ho SB, Kanwal F, Gifford AL, Asch SM. J Hepatol. 2012 Apr 17. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22521358.1

 

Relationship between hepatitis C virus infection and type 2 diabetes mellitus: Meta-analysis. Naing C, Mak JW, Ahmed SI, Maung M. World J Gastroenterol. 2012 Apr 14;18 (14):1642-51.

http://www.ncbi.nlm.nih.gov/pubmed/22529694.1

 

Comparison of hepatitis C virus treatment between incarcerated and community patients.

Rice JP, Burnett D, Tsotsis H, et al. Hepatology. 2012 Apr 13. doi: 10.1002/hep.25770. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22505121.1

 

The high comorbidity burden of the hepatitis C virus infected population in the United States. Louie KS, St Laurent S, Forssen UM, Mundy LM, Pimenta JM. BMC Infect Dis. 2012 Apr 11;12(1):86. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22494445.1

 

Liver Cancer

 

Epidermal growth factor gene polymorphism 61A/G in patients with chronic liver disease for early detection of hepatocellular carcinoma: a pilot study. Abbas E, Shaker O, Abd El Aziz G, Ramadan H, Esmat G. Eur J Gastroenterol Hepatol. 2012 Apr;24(4):458-63.

http://www.ncbi.nlm.nih.gov/pubmed/22293333.1

 

Hepatitis C virus network based classification of hepatocellular cirrhosis and carcinoma.

Huang T, Wang J, Cai YD, Yu H, Chou KC. PLoS One. 2012;7(4):e34460. Epub 2012 Apr 6.

http://www.ncbi.nlm.nih.gov/pubmed/22493692.1